MeiraGTx announces Q3 earnings per share of 62 cents, compared to a loss of 55 cents in the previous year.
Q3 Financial Performance: The company reported Q3 revenue of $410,000, a significant decrease from $10.9 million last year, while announcing a strategic collaboration with Eli Lilly focused on gene therapy for LCA4, a severe inherited retinopathy.
Gene Therapy Advancements: The AAV-AIPL1 program has shown promising results, with all 11 treated children gaining vision, highlighting the potential of gene therapy for severe genetic conditions when administered early.
Clinical Program Progress: The company is on track with its Phase 2 study of AAV-hAQP1 for radiation-induced xerostomia, expecting to complete enrollment by year-end and potentially file for a BLA in early 2027.
New Initiatives and Collaborations: The company is preparing to initiate a Phase 3 study for AAV-GAD in Parkinson's disease and has optimized its riboswitch program for leptin deficiency, while also developing a treatment for BBS10-associated retinal dystrophy in collaboration with a philanthropic organization.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on MGTX
About MGTX
About the author
Eli Lilly Enhances Genetic Eye Disease Pipeline Through Collaboration with MeiraGTx on Gene Therapy
MeiraGTx and Eli Lilly Collaboration: MeiraGTx Holdings has entered a strategic partnership with Eli Lilly, granting exclusive rights to its AAV-AIPL1 program for treating Leber congenital amaurosis 4, with an upfront payment of $75 million and potential milestone payments exceeding $400 million.
Clinical Success of AAV-AIPL1: Clinical trials showed that all 11 children treated with AAV-AIPL1 gained vision, with additional improvements in communication, behavior, learning, and social integration.
Riboswitch Technology: The collaboration includes access to MeiraGTx’s riboswitch technology for gene editing in ophthalmology, allowing precise control over therapeutic protein production through oral dosing.
SanegeneBio and Eli Lilly Partnership: SanegeneBio has also partnered with Eli Lilly to advance RNAi candidates for metabolic diseases, with potential milestone payments up to $1.2 billion and a focus on developing therapies that can be administered infrequently.
Eli Lilly Partners with MeiraGTx to Create Gene Therapies for Ocular Disorders
Collaboration Announcement: MeiraGTx (MGTX) shares rose approximately 18% in premarket trading after announcing a strategic collaboration with Eli Lilly (LLY) to develop gene therapies for eye diseases, specifically targeting Leber congenital amaurosis 4 (LCA4).
Exclusive Rights and Financial Terms: Under the agreement, Eli Lilly will receive exclusive global rights to MGTX's AAV-AIPL1 gene therapy program and other gene therapy technologies, with MeiraGTx set to receive $75 million upfront and over $400 million based on milestone achievements, along with tiered royalties on future sales.
